RIGL Rigel Pharmaceuticals, Inc.

2.51
+0.09  (3.72%)
Previous Close 2.42
Open 2.44
Price To book 3.63
Market Cap 248.33M
Shares 98,937,000
Volume 444,254
Short Ratio 6.00
Av. Daily Volume 1,182,960

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data released January 5, 2017. Full data due in 2018.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Phase 3 data from the first trial released August 30 2016. Primary endpoint met. Data from second trial did not meet the primary endpoint. NDA filing due 1Q 2017.
Fostamatinib
Immune Thrombocytopenic Purpura (ITP)
Phase 2 data from first of two stages due in 2017.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)

Latest News

  1. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  2. Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
  3. Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
  4. Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio?
  5. Hedge Funds Think The Sky’s The Limit For Horizon Global Corp (HZN)
  6. Rigel to Present at Jefferies 2016 London Healthcare Conference
  7. RIGEL PHARMACEUTICALS INC Financials
  8. ETF’s with exposure to Rigel Pharmaceuticals, Inc. : November 4, 2016
  9. Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
  10. Edited Transcript of RIGL earnings conference call or presentation 1-Nov-16 9:00pm GMT
  11. RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  12. Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update
  13. Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update
  14. Q3 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close
  15. Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results
  16. Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results
  17. 4 Companies That Destroyed Shareholders Last Week
  18. Rigel Tanks After Late-Stage Drug Failure (RIGL)
  19. Rigel’s stock rocked as all-in drug disappoints in late-stage trial
  20. Why Rigel Pharma Is Falling

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17525949
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162045699
  3. CT ORDER - Confidential treatment order 162007780
  4. S-8 - Securities to be offered to employees in employee benefit plans 161965532
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161965023
  6. 8-K - Current report 161964964
  7. 8-K - Current report 161943522
  8. 8-K - Current report 161931617
  9. 8-K - Current report 161886286
  10. 8-K - Current report 161859242